Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
about
MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activationCardiovascular outcomes in trials of oral diabetes medications: a systematic reviewNonalcoholic fatty liver disease: an emerging threat to obese and diabetic individualsNon-alcoholic fatty liver disease: what the clinician needs to know.Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemicThiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitroA multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapyComparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesPPARs and the cardiovascular systemLong-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisDiabetes Drugs and Cardiovascular SafetyPPARs: Protectors or Opponents of Myocardial Function?Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Adiponectin as a potential biomarker of vascular diseaseType 2 diabetes and cognitive impairment: linking mechanismsCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsModulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsThe contribution of prostaglandins versus prostacyclin in ventricular remodeling during heart failureSomething old, something new and something very old: drugs for treating type 2 diabetesDiagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of EndocrinologySystematic reviews to ascertain the safety of diabetes medicationsAfter avandia: the use of antidiabetic drugs in patients with heart failureShould antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?Updates on the management of diabetes in dialysis patientsPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyEffect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trialsAssociation between extent of thiazolidinedione exposure and risk of acute myocardial infarctionRosiglitazone and myocardial infarction in patients previously prescribed metforminPioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot studyEffect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trialsThe Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in MiceDivergent roles for adiponectin receptor 1 (AdipoR1) and AdipoR2 in mediating revascularization and metabolic dysfunction in vivo.Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathologyRecommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisComparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.The current role of thiazolidinediones in diabetes management.Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management.Should all women with PCOS be treated for insulin resistance?
P2860
Q21342745-9C000946-9408-4BA8-974E-3EC75D66DF81Q22253058-35613C9B-665D-4080-891D-D7EADD7AF22BQ22299426-1DD5FC3B-B906-4665-A289-2DEE15B3179BQ24563068-C7D01AFE-13E0-4FA6-8C82-5AF39BDC35ABQ24563381-4CBAF3D1-A411-4257-AB95-440F6EC3AFCDQ24608491-05E31365-30F7-4EA2-BC3E-5A5F8B1657F7Q24616813-CEEE4B73-55B0-4141-A9EF-EB7DD287619DQ24632655-11842803-6D93-4984-B376-3DE375E85DA5Q24642503-B70AC4DC-2852-4242-970A-C0E6E38B224AQ24642728-7D0B8162-0366-4B77-9699-A866E030464AQ24655666-0ACED9EB-5A9E-4531-A969-0C0C0FA4D448Q26746085-2A0B5FB6-2ECF-47D2-B4F0-6598FA471213Q26771753-81C41175-C42A-4404-BB84-3307014C30A8Q26777994-21006648-CCBE-4B1D-BEF3-D2C6ACAEE324Q26821925-C3620667-D315-4918-8D49-044F33E9F8C4Q26822993-8F32AB60-1C80-47A1-AC0B-6EB79796E0F1Q26824616-8B78FF42-64B3-4350-BCC8-0F893B8B7EDBQ26829098-265697C8-E213-42BD-AE92-6FC9491FA8F4Q26830372-FD42A73B-1D71-4E4F-8FB8-358269F35BA1Q26865663-378A21AA-8A62-4AB0-9CEE-6113FDDBD2E4Q26998471-4B5099B6-8E7E-4A4C-96B4-221784AD36CBQ27000766-28712765-90D0-4882-867E-4C20D895D9C1Q27021166-E78F9E5D-2D18-4D0F-89FD-B4B848CF5F3AQ27022813-069CC7D5-F7FB-403C-A5AF-3F7975D6A30EQ27024782-F01B4B4A-0A36-425D-9CAF-D825362DADC3Q27024799-9E73D0ED-131E-4317-A6F5-8019A546AE90Q28256514-F10C31BB-DF07-4F54-906C-6626CFA54FA1Q28396990-047452C6-7570-4BB7-9646-A4BB7645028BQ28475672-DAB7D870-B520-4AE2-A06E-F969CD844CF8Q28481414-B802AD0F-7CC7-41D0-9E82-FDD33D45F5FEQ28543544-DBEFC3CA-861E-4421-8914-6907DCE94385Q28552063-33D2789A-56A0-41B1-BFA8-8BC7183357D2Q28591569-BB070759-4ABE-4064-BC48-D0DB284664EBQ28594423-EC4BCCBA-2EB1-4BA1-B228-E4B8C4A6F6B2Q28607750-31687A6F-152B-47D2-93EE-184DE567E23CQ30248535-25A2961F-3091-4B30-AE73-8AC32C81248AQ30250347-CE155ABF-39A1-4EF7-9870-53914EDDAB79Q30384663-5F55E27F-3CFF-49EB-B986-A49501EA2CA8Q30404697-C23B9891-2570-4D92-BA75-1419C591D89AQ30423117-F8FBC627-383E-4521-BF4B-EB5A057620D7
P2860
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@ast
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@en
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@nl
type
label
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@ast
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@en
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@nl
prefLabel
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@ast
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@en
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@nl
P2093
P921
P356
P1476
Pioglitazone and risk of cardi ...... analysis of randomized trials.
@en
P2093
Kathy Wolski
Stephen J Nicholls
Steven E Nissen
P304
P356
10.1001/JAMA.298.10.1180
P407
P577
2007-09-01T00:00:00Z